Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Dec;67(6):763–768. doi: 10.1136/jnnp.67.6.763

BCL-2 Family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy

H Strik 1, M Deininger 1, J Streffer 1, E Grote 1, J Wickboldt 1, J Dichgans 1, M Weller 1, R Meyermann 1
PMCID: PMC1736652  PMID: 10567494

Abstract

OBJECTIVE—In vitro studies indicate a role of apoptosis regulatory proteins of the BCL-2 family in the resistance of glioblastoma multiforme to irradiation and chemotherapy. To date, no study has compared the expression of these proteins in initial and recurrent tumours. The differences of expression of BCL-2, BCL-X, BAX, and MCL-1 proteins of paired first resection and recurrence glioblastoma specimens were examined.
METHODS—Immunohistochemistry was performed in 37 cases of glioblastoma multiforme with paraffin embedded tissue from first resections and their recurrences in three treatment groups (15 radiochemotherapy, 15 irradiation, seven untreated). Ten high power fields were evaluated with an arbitrary score (< 5%=1, 5-50%=2, >50%=3), and cumulative scores for each antigen calculated.
RESULTS—In the whole group, we found a significant up regulation of antiapoptotic BCL-2 (median cumulative score of 15 in the primary, 19 at recurrence; p<0.0001 in the Wilcoxon test), BCLX (median scores 20 and 25, respectively, p<0.0001), and MCL-1 (median scores 11 and 14, p=0.0395), and a significant down regulation of proapoptotic BAX (median scores 14 and 11, p<0.0001). In the subgroups, these trends were also found. No association between protein expression and treatment regimen was found, although significant changes were restricted to the subgroups that received adjuvant chemotherapy. No significant correlation with clinical prognosis was detected with the Kaplan-Meier method.
CONCLUSIONS—In the development from initial to recurrent glioblastoma multiforme, the BCL-2 family rheostat shifts towards antiapoptotic adjustment in vivo. Importantly, the changes in BCL-2 family protein expression characterised here were also seen in the subgroup of patients who did not receive adjuvant radiotherapy or chemotherapy, suggesting that the changes of BCL-2 family protein expression result not only from radiochemotherapy but also reflect the natural course of disease.



Full Text

The Full Text of this article is available as a PDF (153.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson L. M., Castleberg R. L., Harsh G. R., 4th, Louis D. N., Henson J. W. Human gliomas with wild-type p53 express bcl-2. Cancer Res. 1995 Mar 1;55(5):999–1001. [PubMed] [Google Scholar]
  2. Boise L. H., González-García M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nuñez G., Thompson C. B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993 Aug 27;74(4):597–608. doi: 10.1016/0092-8674(93)90508-n. [DOI] [PubMed] [Google Scholar]
  3. Ellison D. W., Steart P. V., Gatter K. C., Weller R. O. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol. 1995 Aug;21(4):352–361. doi: 10.1111/j.1365-2990.1995.tb01070.x. [DOI] [PubMed] [Google Scholar]
  4. Frassoldati A., Adami F., Banzi C., Criscuolo M., Piccinini L., Silingardi V. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat. 1997 Jul;44(3):185–192. doi: 10.1023/a:1005875002458. [DOI] [PubMed] [Google Scholar]
  5. Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W., Giaccia A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996 Jan 4;379(6560):88–91. doi: 10.1038/379088a0. [DOI] [PubMed] [Google Scholar]
  6. Hirakawa K., Suzuki K., Ueda S., Nakagawa Y., Yoshino E., Ibayashi N., Hayashi K. Multivariate analysis of factors affecting postoperative survival in malignant astrocytoma. Importance of DNA quantification. J Neurooncol. 1984;2(4):331–340. doi: 10.1007/BF00178116. [DOI] [PubMed] [Google Scholar]
  7. Ikeguchi M., Tatebe S., Kaibara N., Ito H. Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Eur Surg Res. 1997;29(5):396–402. doi: 10.1159/000129549. [DOI] [PubMed] [Google Scholar]
  8. Krajewski S., Krajewska M., Ehrmann J., Sikorska M., Lach B., Chatten J., Reed J. C. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol. 1997 Mar;150(3):805–814. [PMC free article] [PubMed] [Google Scholar]
  9. Krishna M., Smith T. W., Recht L. D. Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J Neurosurg. 1995 Dec;83(6):1017–1022. doi: 10.3171/jns.1995.83.6.1017. [DOI] [PubMed] [Google Scholar]
  10. Nakasu S., Nakasu Y., Nioka H., Nakajima M., Handa J. bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol. 1994;88(6):520–526. doi: 10.1007/BF00296488. [DOI] [PubMed] [Google Scholar]
  11. Newcomb E. W., Bhalla S. K., Parrish C. L., Hayes R. L., Cohen H., Miller D. C. bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol. 1997 Oct;94(4):369–375. doi: 10.1007/s004010050721. [DOI] [PubMed] [Google Scholar]
  12. Newcomb E. W., Cohen H., Lee S. R., Bhalla S. K., Bloom J., Hayes R. L., Miller D. C. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998 Oct;8(4):655–667. doi: 10.1111/j.1750-3639.1998.tb00191.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ogretmen B., Safa A. R. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer. 1996 Sep 4;67(5):608–614. doi: 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  14. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993 Aug 27;74(4):609–619. doi: 10.1016/0092-8674(93)90509-o. [DOI] [PubMed] [Google Scholar]
  15. Palazzo J. P., Kafka N. J., Grasso L., Chakrani F., Hanau C., Cuesta K. H., Mercer W. E. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. Hum Pathol. 1997 Oct;28(10):1189–1195. doi: 10.1016/s0046-8177(97)90257-4. [DOI] [PubMed] [Google Scholar]
  16. Rieger L., Weller M., Bornemann A., Schabet M., Dichgans J., Meyermann R. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci. 1998 Feb 18;155(1):68–75. doi: 10.1016/s0022-510x(97)00277-3. [DOI] [PubMed] [Google Scholar]
  17. Sakakura C., Sweeney E. A., Shirahama T., Igarashi Y., Hakomori S., Nakatani H., Tsujimoto H., Imanishi T., Ohgaki M., Ohyama T. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer. 1996 Jul 3;67(1):101–105. doi: 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  18. Schiffer D., Cavalla P., Migheli A., Giordana M. T., Chiadò-Piat L. Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neurooncol. 1996 Feb;27(2):101–109. doi: 10.1007/BF00177472. [DOI] [PubMed] [Google Scholar]
  19. Shimizu S., Eguchi Y., Kamiike W., Itoh Y., Hasegawa J., Yamabe K., Otsuki Y., Matsuda H., Tsujimoto Y. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res. 1996 May 1;56(9):2161–2166. [PubMed] [Google Scholar]
  20. Simonian P. L., Grillot D. A., Merino R., Nuñez G. Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL. J Biol Chem. 1996 Sep 13;271(37):22764–22772. doi: 10.1074/jbc.271.37.22764. [DOI] [PubMed] [Google Scholar]
  21. Tsujimoto Y., Shimizu S., Eguchi Y., Kamiike W., Matsuda H. Bcl-2 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways. Leukemia. 1997 Apr;11 (Suppl 3):380–382. [PubMed] [Google Scholar]
  22. Tu Y., Xu F. H., Liu J., Vescio R., Berenson J., Fady C., Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood. 1996 Sep 1;88(5):1805–1812. [PubMed] [Google Scholar]
  23. Walker M. D., Alexander E., Jr, Hunt W. E., MacCarty C. S., Mahaley M. S., Jr, Mealey J., Jr, Norrell H. A., Owens G., Ransohoff J., Wilson C. B. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333–343. doi: 10.3171/jns.1978.49.3.0333. [DOI] [PubMed] [Google Scholar]
  24. Watanabe K., Tachibana O., Yonekawa Y., Kleihues P., Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Invest. 1997 Feb;76(2):277–284. [PubMed] [Google Scholar]
  25. Weller M., Malipiero U., Aguzzi A., Reed J. C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 1995 Jun;95(6):2633–2643. doi: 10.1172/JCI117965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998 Jun;292(3):435–445. doi: 10.1007/s004410051072. [DOI] [PubMed] [Google Scholar]
  27. Weller M., Winter S., Schmidt C., Esser P., Fontana A., Dichgans J., Groscurth P. Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int J Cancer. 1997 Nov 27;73(5):707–714. doi: 10.1002/(sici)1097-0215(19971127)73:5<707::aid-ijc16>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES